A 16-WEEK, SINGLE CENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED, PARALLEL GROUP, PHASE 3B TRIAL TO EVALUATE THE EFFICACY OF SAXAGLIPTIN CO-ADMINISTERED WITH DAPAGLIFLOZIN COMPARED TO DAPAGLIFLOZIN WITH REGARD TO ENDOGENOUS GLUCOSE PRODUCTION
Principal Investigator(s)
Cersosimo,Eugenio
Funded by
ASTRAZENECA PHARMACEUTICALS
Research Start Date
Status
Active